Fondaparinux causes bleeding, as can venlafaxine ; concurrent use might increase the risk of developing this effect. Formoterol is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Fosamprenavir is predicted to increase the exposure to venlafaxine. Both venlafaxine and frovatriptan can increase the risk of serotonin syndrome. Furosemide is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine.
Both venlafaxine and glasdegib prolong the QT interval. Both venlafaxine and granisetron can increase the risk of serotonin syndrome. Granisetron is predicted to increase the risk of QT-prolongation when given with venlafaxine. Both venlafaxine and haloperidol prolong the QT interval. Venlafaxine slightly increases the exposure to haloperidol.
Heparin causes bleeding, as can venlafaxine ; concurrent use might increase the risk of developing this effect. Hydrochlorothiazide is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine.
Hydrocortisone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Hydroflumethiazide is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine.
Both venlafaxine and hydroxyzine prolong the QT interval. Both venlafaxine and ibrutinib can increase the risk of bleeding. Both venlafaxine and ibuprofen can increase the risk of bleeding. Idelalisib is predicted to increase the exposure to venlafaxine. Both venlafaxine and iloprost can increase the risk of bleeding.
Both venlafaxine and imatinib can increase the risk of bleeding. Both venlafaxine and imipramine can increase the risk of serotonin syndrome. Indacaterol is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Indapamide is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine.
Both venlafaxine and indometacin can increase the risk of bleeding. Venlafaxine causes bleeding, as can inotersen ; concurrent use might increase the risk of developing this effect. Inotuzumab ozogamicin. Both venlafaxine and inotuzumab ozogamicin prolong the QT interval. Both venlafaxine and isocarboxazid can increase the risk of serotonin syndrome. Both venlafaxine and isoflurane prolong the QT interval. Itraconazole is predicted to increase the exposure to venlafaxine. Ivabradine is predicted to increase the risk of torsade de pointes when given with venlafaxine.
Ketoconazole is predicted to increase the exposure to venlafaxine. Both venlafaxine and ketoprofen can increase the risk of bleeding. Both venlafaxine and ketorolac can increase the risk of bleeding. Both venlafaxine and lapatinib prolong the QT interval. Both venlafaxine and lenvatinib prolong the QT interval. Both venlafaxine and lenvatinib can increase the risk of bleeding. Both venlafaxine and levomepromazine prolong the QT interval.
Both venlafaxine and linezolid can increase the risk of serotonin syndrome. Both venlafaxine and lisdexamfetamine can increase the risk of serotonin syndrome. Both venlafaxine and lithium can increase the risk of serotonin syndrome.
Both venlafaxine and lithium prolong the QT interval. Both venlafaxine and lofexidine prolong the QT interval. Lopinavir is predicted to increase the exposure to venlafaxine. Mefenamic acid. Both venlafaxine and mefenamic acid can increase the risk of bleeding. Mefloquine is predicted to increase the risk of QT-prolongation when given with venlafaxine. Both venlafaxine and meloxicam can increase the risk of bleeding.
Both venlafaxine and methadone can increase the risk of serotonin syndrome. Both venlafaxine and methadone prolong the QT interval. Methylprednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine.
Methylthioninium chloride. Both venlafaxine and methylthioninium chloride can increase the risk of serotonin syndrome. Metolazone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Both venlafaxine and mirtazapine can increase the risk of serotonin syndrome.
Mizolastine is predicted to increase the risk of QT-prolongation when given with venlafaxine. Both venlafaxine and moclobemide can increase the risk of serotonin syndrome. Both venlafaxine and moxifloxacin prolong the QT interval. Both venlafaxine and nabumetone can increase the risk of bleeding. Both venlafaxine and naproxen can increase the risk of bleeding. Both venlafaxine and naratriptan can increase the risk of serotonin syndrome. Nicotinic acid. Nicotinic acid causes bleeding, as can venlafaxine ; concurrent use might increase the risk of developing this effect.
Both venlafaxine and nilotinib prolong the QT interval. Both venlafaxine and nintedanib can increase the risk of bleeding. Nitrous oxide. Olodaterol is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Omegaacid ethyl esters. Both venlafaxine and omegaacid ethyl esters can increase the risk of bleeding. Both venlafaxine and ondansetron can increase the risk of serotonin syndrome.
Both venlafaxine and ondansetron prolong the QT interval. Both venlafaxine and osilodrostat prolong the QT interval. Both venlafaxine and osimertinib prolong the QT interval. Ozanimod might increase the risk of QT-prolongation when given with venlafaxine.
Both venlafaxine and paliperidone prolong the QT interval. Both venlafaxine and palonosetron can increase the risk of serotonin syndrome. Palonosetron is predicted to increase the risk of QT-prolongation when given with venlafaxine.
Both venlafaxine and panobinostat prolong the QT interval. Both venlafaxine and parecoxib can increase the risk of bleeding. Both venlafaxine and paroxetine can increase the risk of serotonin syndrome. Both venlafaxine and paroxetine can increase the risk of bleeding. Both venlafaxine and pasireotide prolong the QT interval. Both venlafaxine and pazopanib prolong the QT interval. Both venlafaxine and pazopanib can increase the risk of bleeding.
Intravenous pentamidine potentially increases the risk of QT-prolongation when given with venlafaxine. Both venlafaxine and pentazocine can increase the risk of serotonin syndrome. Both venlafaxine and pethidine can increase the risk of serotonin syndrome. Both venlafaxine and phenazone can increase the risk of bleeding. Both venlafaxine and phenelzine can increase the risk of serotonin syndrome. Phenindione causes bleeding, as can venlafaxine ; concurrent use might increase the risk of developing this effect.
Both venlafaxine and pimozide prolong the QT interval. Both venlafaxine and piroxicam can increase the risk of bleeding. Venlafaxine is predicted to increase the exposure to pitolisant. Manufacturer advises use with caution and adjust dose. Both venlafaxine and ponatinib can increase the risk of bleeding.
Both venlafaxine and prasugrel can increase the risk of bleeding. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with venlafaxine. Both venlafaxine and quinine prolong the QT interval. Both venlafaxine and ranolazine prolong the QT interval. Both venlafaxine and rasagiline can increase the risk of serotonin syndrome. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. If you will be taking this medicine for a long time, it is very important that your doctor check you at regular visits.
This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. Do not start taking venlafaxine during the 14 days after you stop a MAO inhibitor and wait 7 days after stopping venlafaxine before you start taking a MAO inhibitor. If you take them together or do not wait the proper amount of time, you may develop confusion, agitation, restlessness, stomach or intestinal symptoms, a sudden high body temperature, an extremely high blood pressure, or severe seizures.
Venlafaxine may cause a serious condition called serotonin syndrome if taken together with certain medicines. Check with your doctor first before taking any other medicines with venlafaxine. This medicine may cause some teenagers and young adults to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed.
Some people may have trouble sleeping, get upset easily, have a big increase in energy, or start to act reckless. If you or your caregiver notice any of these unwanted effects, tell your doctor right away. Let the doctor know if you or anyone in your family has bipolar disorder manic-depressive or has tried to commit suicide.
Do not suddenly stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are taking before stopping it completely. This will decrease the chance of side effects, such as agitation, confusion, headache, irritability, numbness or tingling feeling, restlessness, trouble sleeping, or unusual drowsiness or weakness. This medicine may cause hyponatremia low sodium in the blood. This is more common in elderly patients, those who take diuretic medicines, or those who have a low amount of fluid in the body due to severe diarrhea or vomiting.
Check with your doctor right away if you have a headache, trouble concentrating, memory problems, confusion, weakness, or feel unsteady when standing. Venlafaxine may increase your risk for bleeding problems.
Tell your doctor right away if you are having chest pain or discomfort, dry cough, fever, general feeling of tiredness or weakness, skin rash, or trouble breathing with this medicine.
These might be symptoms of a serious lung problem, including interstitial lung disease and eosinophilic pneumonia. Venlafaxine may cause some people to become drowsy or have blurred vision. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert or able to see clearly.
It is best to avoid alcohol with venlafaxine. Before you have any medical tests, tell the medical doctor in charge that you are taking this medicine. The results of some tests may be affected by this medicine. Check with your doctor right away if you have decreased interest in sexual intercourse, delayed or inability to have and orgasm in women, inability to have or keep an erection in men, or loss in sexual ability, desire, drive, or performance.
Skip to content Home Psychology Can you take amitriptyline and Effexor together? Ben Davis March 6, Can you take amitriptyline and Effexor together? Does Effexor interact with gabapentin? What medications should not be taken with amitriptyline? What is Amitriptyline 10 mg prescribed for?
Can I take amitriptyline and gabapentin at the same time? How much amitriptyline can I take for nerve pain? Does Amitriptyline 10mg cause weight gain? Is amitriptyline linked to dementia?
0コメント